Share your videos with the world

Sign Up | Log In | Help  

   
 
Search // eluting
Results 1-3 of 3 for ' eluting ' (0 seconds)
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months. The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers. To view the multimedia release go to: http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Categories // Science and Technology 
Added: 3335 days ago by MultiVuVideos
Runtime: 0m45s | Views: 738 | Comments: 2
Not yet rated
 

 

 

OhioHealth Riverside Methodist Hospital is now treating patients with peripheral artery disease (PAD) with the first drug-eluting stent to be used outside of the heart. Cook Medical’s Zilver PTX is a drug-coated stent that is used to reopen a long thigh artery, located above the knee (the femoropopliteal artery), narrowed or blocked due to PAD. This is the most common artery for PAD blockages. To view Multimedia News Release, go to http://www.multivu.com/mnr/60291-ohiohealth-riverside-hospital-zilver-ptx-drug-coated-stent-for-pad
Categories // Science and Technology 
Added: 4282 days ago by MultiVuVideos
Runtime: 2m3s | Views: 1115 | Comments: 0
Not yet rated
 

 

 

Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately. To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Categories // Science and Technology 
Added: 4740 days ago by MultiVuVideos
Runtime: 2m30s | Views: 5508 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.